Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Salvatore, Michael F ^a   Pruett, Brandon S ^a   Spann, Sandy L ^a   Dempsey, Charles ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; LOCOMOTION; NONHUMAN; NUCLEUS ACCUMBENS; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

AGING; ANIMALS; BIOLOGICAL AVAILABILITY; DOPAMINE; LONGEVITY; MOTOR ACTIVITY; PHOSPHORYLATION; PHOSPHOSERINE; POPULATION DYNAMICS; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 77949517848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008466     Document Type: Article

References (69)

1. Bennet DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, et al. (1996) Prevalence of Parkinsonian signs and associated mortality in a community population of older people. New England J Med 334: 71-76.
2. Prettyman R (1998) Extrapyramidal signs in cognitively intact elderly people. Age and Ageing 27: 557-560.
3. Fleischman DA, Wilson RS, Schneider JA, Beinias JL, Bennet DA (2007) Parkinsonian signs and functional disability in old age. Exp Aging Res 33: 59-76.
4. Murray AM, Bennett DA, Mendes de Leon CF, Beckett LA, Evans DA (2004) A longitudinal study of Parkinsonism and disability in a community population of older people. J Gerontol: Medical Sciences 59A: 864-870.
5. Buchman AS, Boyle PA, Wilson RS, Fleischman DA, Leurgans S, et al. (2009) Association between late-life social activity and motor decline in older adults. Arch Intern Med 169: 1139-1146.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurological Sci 20: 415-455.
7. Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 195: 123-137.
8. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. In Advances in Neurology, M.D. Yahr and K.J. Bergmann, eds (Raven Press), pp 19-34.
9. Hudson JL, Van Horne CG, Stromberg I, Brock S, Clayton J, et al. (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostri- atal dopamine content in unilateral 6- hydroxydopamine lesioned rats. Brain Res 626: 167-174.
10. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine- lesioned Macaque model of Parkinson's disease. J Neurosci 21: 6853-6861.
11. Kish SJ, Shannak K, Rajput A, Deck JHN, Hornykiewicz O (1992) Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease. J Neurochem 58: 642-648.
12. Hebert MA, Gerhardt GA (1998) Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats. Brain Res 797: 42-54.
13. Yurek DM, Hipkens SB, Hebert MA, Gash DM, Gerhardt GA (1998) Age- related decline in striatal dopamine release and motoric function in Brown Norway/Fischer 344 hybrid rats. Brain Res 791: 246-256.
14. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM (2002) Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80: 168-177.
15. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, et al. (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87: 574-585.
16. Wolf ME, LeWitt PA, Bannon MJ, Dragovic LJ, Kapatos G (1991) Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J Neurochem 56: 1191-1200.
17. Irwin I, DeLanney LE, McNeill T, Chan P, Forno LS, et al. (1994) Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegen- eration 3: 251-265.
18. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, et al. (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123: 366-373.
19. Salvatore MF, Apparsundaram S, Gerhardt GA (2003) Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 24: 1147-1154.
20. McCormack AL, DiMonte DA, Delfani K, Irwin I, DeLanney LE, et al. (2004) Aging of the nigrostriatal system in the Squirrel monkey. J Comp Neurol 471: 387-395.
21. Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals: Multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266: 5650-5657.
22. Haycock JW, Lew JY, Garcia-Espana A, Lee KY, Harada K, et al. (1998) Role of Serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site- and phosphospecific antibodies and site-directed mutagenesis. J Neurochem 71: 1670-1675.
23. Haycock JW (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19,31, and 40. J. Biol. Chem. 265, 11682-11691.
24. Waymire JC, Craviso GL, Lichteig K, Johnston JP, Baldwin C, et al. (1991) Vasoactive intestinal peptide stimulates catecholamine biosynthesis in isolated adrenal chromaffin cells: Evidence for a cyclic AMP-dependent phosphorylationand activation of tyrosine hydroxylase. J Neurochem 57: 1313-1324.
25. Salvatore MF, Waymire JC, Haycock JW (2001) Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79: 349-360.
26. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91: 1025-1043.
27. Salvatore MF, Fischer, B, Surgener SP, Gerhardt GA, Rouault TA (2005) Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Mol Brain Res 139: 341-347.
28. Conner JR, Wang X-S, Allen, RP, Beard JL, Wiesinger JA, et al. (2009) Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 132: 2403-2412.
29. Harada K, Wu J, Haycock JW, Goldstein M (1996) Regulation of L-DOPA biosynthesis by site-specific phosphorylation of tyrosine hydroxylase in AtT-20 cells expressing wild-type and serine 40-substituted enzyme. J Neurochem 67: 629-635.
30. Parkinson JA, Olmstead MC, Burns LH, Robbins TW, Everitt BJ (1999) Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by D-amphetamine. J Neurosci 19: 2401-2411.
31. Palmiter RD (2008) Dopamine signaling in the dorsal striatum is essential for motivated behaviors. Ann NY Acad Sci 1129: 35-46.
32. Huang R-L, Wang C-T, Tai M-Y, Tsai YF, Peng MT (1995) Effects of age on dopamine release in the nucleus accumbens and amphetamine-induced locomotor activity in rats. Neurosci Lett 200: 61-64.
33. Beeler JA, Cao ZFH, Kheirbek MA, Zhuang X (2008) Loss of Cocaine Locomotor Response in Pitx3-Deficient Mice Lacking a Nigrostriatal Pathway. Neuropsychopharm 34: 1149-1161.
34. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289: 537-542.
35. Fortin GD, Desrosiers CC, Yamaguchi N, Trudeau LE (2006) Basal somatodendritic dopamine release requires snare proteins. J Neurochem 96: 1749-1749.
36. Hoffman AF, Lupica CR, Gerhardt GA (1998) Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J Pharmacol Exp Ther 287: 487-496.
37. Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58: 303-313.
38. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, et al. (1998) Age- related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401: 253-265.
39. Andersson DR, Nissbrandt H, Bergquist F (2006) Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 24: 617-624.
40. Robertson GS, Robertson HA (1989) Evidence that L-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9:3326-3331.
41. Trevitt JT, Carlson BB, Nowend K, Salamone JD (2001) Substantia nigra pars reticulate is a highly potent site of action for the behavioral effects of the D1 antagonist SCH23390 in rat. Psychopharmacol 156: 32-41.
42. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114: 2283-2301.
43. Sanchez HL, Silva LB, Portiansky EL, Herenu CB, Goya RG, et al. (2008) Dopaminergic mesencephalic systems and behavioral performance in very old rats. Neuroscience 154: 1598-1606.
44. Ponzio F, Calderini G, Lomuscio G, Vantini G, Toffano G, et al. (1982) Changes in monoamines and their metabolite levels in some brain regions of aged rats. Neurobiol Aging 3: 23-29.
45. Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, et al. (2008) Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 115: 461-470.
46. Hoffer BJ, Hoffman AF, Bowenkamp KE, Huettl P, Hudson J, et al. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182: 107-111.
47. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
48. Hebert MA, Gerhardt GA (1997) Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharm Exp Ther 282: 760-768.
49. Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, et al. (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged Rhesus monkeys. J Neurosci 23: 1974-1980.
50. Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, et al. (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in rat striatum and substantia nigra. J Neurochem 90, 245-254.
51. Salvatore MF, Gerhardt GA, Dayton RD, Klein RL, Stanford JA (2009) Bilateral effects of unilateral GDNF administration on dopamine- and GABA- regulating proteins in the rat nigrostriatal system. Exp Neurol 219: 197-207.
52. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, et al. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputamenal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222.
53. Spangler EL, Waggie KS, Hengemihle J, Roberts D, Hess B, et al. (1994) Behavioral assessment of aging in male Fischer 344 and Brown-Norway rat strains and their F1 hybrid. Neurobiol Aging 15: 319-328.
54. Cruz-Muros I, Afonso-Oramas D, Abreu P, Barroso-Chinea P, Rodríguez M (2007) Aging of the rat mesostriatal system: Differences between the nigrostriatal and the mesolimbic compartments. Exp Neurol 204: 147-161.
55. Phelan JP, Austad SN (1994) Selecting animal models of human aging: Inbred strains often exhibit less biological uniformity than F1 hybrids. J Gerontol 49: B1-B11.
56. Sprott RL, Rameriz I (1997) Current inbred and hybrid rat and mouse models. ILAR J 38: 1-6.
57. Salvatore MF, Garcia-Espana A, Goldstein M, Deutch AY, Haycock JW (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo. J Neurochem 75: 225-232.
58. Lavicky J, Dunn AJ (1993) Corticotropin-releasing factor stimulates catechol- amine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60: 602-612.
59. Kliem MA, Maidment NT, Ackerson LC, Chen S, Smith Y, et al. (2007) Activation of nigral and pallidal dopamine D1-like receptors modulates basal ganglia outflow in monkeys. J Neurophysiol 98: 1489-1500.
60. Thompson LH, Grealish S, Kirik D, Bjorklund A (2009) Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 30:625-638.
61. Freed CR, Yamamoto BK (1985) Regional brain dopamine metabolism: a marker for the speed, direction, and posture of moving animals. Science 229: 62-65.
62. Marshall JF, Rosenstein AJ (1990) Age-related decline in rat striatal dopamine metabolism is regionally homogeneous. Neurobiol Aging 11: 131-137.
63. Emerich DF, McDermott P, Krueger P, Banks M, Zhao J, et al. (1993) Locomotion of aged rats: Relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons. Brain Res Bull 32: 477-486.
64. Cardozo-Pelaez F, Song S, Parthasarathy A, Hazzi C, Naidu K, et al. (1999) Oxidative DNA damage in the aging mouse brain. Movement Dis 14: 972-980.
65. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, et al. (2007) Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26: 56-65.
66. Cass WA, Harned ME, Bailey SL (2002) Enhanced effects of 6-hydroxydopa- mine on evoked overflow of striatal dopamine in aged rats. Brain Res 938: 29-37.
67. Ossowska K, Wolfarth S, Schulze G, Wardas J, Pietraszek M, et al. (2001) Decline in motor functions in aging is related to the loss of NMDA receptors. Brain Res 907: 71-83.
68. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
69. Brown VJ, Robbins TW (1991) Simple and choice reaction time performance following unilateral striatal dopamine depletion in the rat: Impaired motor readiness but preserved response preparation. Brain 114: 513-525.